Highly Influential Citations6
Claim Your Author Page
BACKGROUND The frequency of aromatase inhibitor (AI)-associated arthralgia and/or bone pain in clinical practice is not known. PATIENTS AND METHODS Fifty-six consecutive patients with breast cancer… Continue Reading
BackgroundIn recent years, a battery-powered bone marrow biopsy system was developed and cleared by the U.S. Food and Drug Administration to allow health care providers to access the bone marrow… Continue Reading
Few studies have evaluated prognostic factors among patients with multiple myeloma (MM) since new therapies have become available. Monthly zoledronic acid (ZOL) has been incorporated into many… Continue Reading
6137 Background: Prior studies of AI have identified A and/or BP as side effects. Reported incidences have varied from 4% (IMPACT) to 35.6% (ATAC). In order to determine the frequency of A or BP in… Continue Reading
8062 Background: BE, a monoclonal antibody that inhibits VEGF, prolongs survival in patients (pts) with metastatic colorectal cancer treated with 5FU chemotherapy. However, BE is associated with HT...
BACKGROUND A drug-induced apoptosis assay has been developed to determine which chemotherapy drugs or regimens can produce higher cell killing in vitro. This study was done to determine if this assay… Continue Reading
e19519 Background: Although the overall survival of MM patients has improved with new treatment options, few studies have evaluated prognostic factors since these new therapies have become available.… Continue Reading
6591 Background: Faster infusion of rituximab (R) can improve patient (pt) convenience and reduce strain on oncology unit resources. To assess the safety, PK and PD of a 90-min infusion rate for R in… Continue Reading
17527 Background: Quality of care (QC) improves when NG are followed in patient (pt) management. Demonstration of COMP with NG is costly and slow (QOPI, and ASCO 2007 abstract 17050). We extended o...